Patrick Roth

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9046888/publications.pdf

Version: 2024-02-01

172 papers	8,513 citations	53794 45 h-index	53230 85 g-index
179 all docs	179 docs citations	179 times ranked	10741 citing authors

#	Article	IF	Citations
1	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro-Oncology, 2023, 25, 123-134.	1.2	150
2	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. Neuro-Oncology, 2022, 24, 1726-1735.	1.2	18
3	Prognostic Relevance of Transforming Growth Factor-Î² Receptor Expression and Signaling in Glioblastoma, Isocitrate Dehydrogenase-Wildtype. Journal of Neuropathology and Experimental Neurology, 2022, 81, 225-235.	1.7	2
4	Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clinical Cancer Research, 2022, 28, 2270-2277.	7.0	30
5	Venous thromboembolic events in glioblastoma patients: An epidemiological study. European Journal of Neurology, 2022, 29, 2386-2397.	3.3	7
6	MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. Clinical Cancer Research, 2021, 27, 179-188.	7.0	16
7	The molecular evolution of glioblastoma treated by gross total resection alone. Neuro-Oncology, 2021, 23, 334-336.	1.2	2
8	Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Annals of Oncology, 2021, 32, 171-182.	1.2	42
9	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology, 2021, 18, 170-186.	27.6	826
10	A vasculature-centric approach to developing novel treatment options for glioblastoma. Expert Opinion on Therapeutic Targets, 2021, 25, 87-100.	3.4	9
11	Chemotherapy for adult patients with spinal cord gliomas. Neuro-Oncology Practice, 2021, 8, 475-484.	1.6	1
12	Telomerase reverse transcriptase promoter mutationâ€“ and O6-methylguanine DNA methyltransferase promoter methylationâ€“mediated sensitivity to temozolomide in isocitrate dehydrogenaseâ€“wild-type glioblastoma: is there a link?. European Journal of Cancer, 2021, 147, 84-94.	2.8	10
13	Neuro-Oncology Practice in 2021: Covid-19, telemedicine, and beyond. Neuro-Oncology Practice, 2021, 8, 107-108.	1.6	1
14	EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2021, 39, 2004-2004.	1.6	18
15	The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2021, 39, TPS2068-TPS2068.	1.6	1
16	Survival of brain tumour patients with epilepsy. Brain, 2021, 144, 3322-3327.	7.6	14
17	Fitness-to-drive for glioblastoma patients. Swiss Medical Weekly, 2021, 151, w20501.	1.6	3
18	Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression. Neuro-Oncology, 2021, 23, 1612-1613.	1.2	1

#	Article	IF	Citations
19	Neurological complications of cancer immunotherapy. Cancer Treatment Reviews, 2021, 97, 102189.	7.7	34
20	Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma. Cancers, 2021, 13, 3073.	3.7	15
21	SYST-03. A PHASE I/II STUDY TO EVALUATE SAFETY AND PRELIMINARY ACTIVITY OF THE TUMOR-TARGETING ANTIBODY-CYTOKINE FUSION PROTEIN L19TNF IN PATIENTS WITH GLIOBLASTOMA AT FIRST RELAPSE. Neuro-Oncology Advances, 2021, 3, iv8-iv9.	0.7	0
22	The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. Cell Death and Disease, 2021, 12, 885.	6.3	22
23	NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. Neuro-Oncology, 2021, 23, vi126-vi127.	1.2	1
24	DDRE-21. LOMUSTINE AND TARGETED-CYTOKINE THERAPY: A BENEFICIAL LIAISON FOR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi78-vi79.	1.2	0
25	IMMU-13. COMBINED MODULATION OF THE TGF-Î² PATHWAY AND GITR IMMUNE CHECKPOINT SIGNALING PROMOTES ANTI-TUMOR IMMUNITY IN SYNGENEIC GLIOMA MODELS. Neuro-Oncology, 2021, 23, vi94-vi94.	1.2	0
26	IMMU-39. EVALUATION OF CD317-TARGETING CAR T CELLS AS A NOVEL IMMUNOTHERAPEUTIC STRATEGY AGAINST GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi101-vi101.	1.2	0
27	EXTH-21. MECHANISMS OF SYNERGISTIC GROWTH SUPPRESSION BY RADIOTHERAPY AND C-MET INHIBITION IN EXPERIMENTAL GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi167-vi168.	1.2	0
28	Risk factors for the development of epilepsy in patients with brain metastases. Neuro-Oncology, 2020, 22, 718-728.	1.2	27
29	Immunocytokines are a promising immunotherapeutic approach against glioblastoma. Science Translational Medicine, 2020, 12, .	12.4	69
30	Proteasome inhibition for the treatment of glioblastoma. Expert Opinion on Investigational Drugs, 2020, 29, 1133-1141.	4.1	28
31	Antidepressant drug use in glioblastoma patients: an epidemiological view. Neuro-Oncology Practice, 2020, 7, 514-521.	1.6	4
32	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. JAMA Oncology, 2020, 6, 1003.	7.1	805
33	Venous thromboembolic events in patients with brain metastases: the PICOS score. European Journal of Cancer, 2020, 134, 75-85.	2.8	11
34	Socioeconomic burden and quality of life in meningioma patients. Quality of Life Research, 2020, 29, 1801-1808.	3.1	11
35	Interferon-Î² exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity. Neuro-Oncology Advances, 2020, 2, vdaa043.	0.7	3
36	End-of-life care for glioma patients; the caregiversâ€™ perspective. Journal of Neuro-Oncology, 2020, 147, 663-669.	2.9	12

#	Article	IF	Citations
37	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	543
38	A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. Swiss Medical Weekly, 2020, 150, w20256.	1.6	5
39	Safety, Tolerability, and Use of Steroids. , 2020, , 127-137.		0
40	Venous thromboembolic events in glioblastoma patients: Common complication but not a major reason for death.. Journal of Clinical Oncology, 2020, 38, e14530-e14530.	1.6	0
41	Targeting glioblastoma with novel immunocytokines.. Journal of Clinical Oncology, 2020, 38, 2558-2558.	1.6	3
42	Association of peripheral blood CD4+ T-cell depletion under temozolomide with inferior survival of patients with IDH wildtype glioblastoma.. Journal of Clinical Oncology, 2020, 38, 2548-2548.	1.6	0
43	The imaging substudy of the randomized ARTE trial: MRI and 18FET PET associations with overall survival benefit from bevacizumab in elderly patients with newly diagnosed IDH wildtype glioblastoma.. Journal of Clinical Oncology, 2020, 38, 2520-2520.	1.6	0
44	IMMU-07. TUMOR STROMAâ€“TARGETING ANTIBODY-CYTOKINE CONJUGATES TO CONVERT THE IMMUNOLOGICALLY COLD GLIOMA MICROENVIRONMENT INTO A HOT ONE. Neuro-Oncology, 2020, 22, ii106-ii106.	1.2	0
45	EPID-36. ANTIDEPRESSANT DRUG USE IN GLIOBLASTOMA PATIENTS: AN EPIDEMIOLOGICAL VIEW. Neuro-Oncology, 2020, 22, ii86-ii86.	1.2	0
46	BIOM-59. TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK?. Neuro-Oncology, 2020, 22, ii14-ii14.	1.2	0
47	How we treat glioblastoma. ESMO Open, 2019, 4, e000520.	4.5	62
48	Molecular targeted therapy of glioblastoma. Cancer Treatment Reviews, 2019, 80, 101896.	7.7	386
49	Highâ€throughput proteomic analysis of <scp>FFPE</scp> tissue samples facilitates tumor stratification. Molecular Oncology, 2019, 13, 2305-2328.	4.6	100
50	Underweight and weight loss are predictors of poor outcome in patients with brain metastasis. Journal of Neuro-Oncology, 2019, 145, 339-347.	2.9	7
51	The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. Neuro-Oncology, 2019, 21, 648-658.	1.2	90
52	EPID-10. VENOUS THROMBOEMBOLIC EVENTS IN GLIOBLASTOMA PATIENTS: AN EPIDEMIOLOGICAL VIEW. Neuro-Oncology, 2019, 21, vi76-vi76.	1.2	0
53	ACTR-33. INFIGRATINIB (BGJ398) IN PATIENTS WITH RECURRENT GLIOMAS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) ALTERATIONS: A MULTICENTER PHASE II STUDY. Neuro-Oncology, 2019, 21, vi20-vi20.	1.2	5
54	IMMU-17. TARGETING GLIOBLASTOMA WITH DNAM-1-BASED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS. Neuro-Oncology, 2019, 21, vi122-vi122.	1.2	0

#	Article	IF	Citations
55	ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. Neuro-Oncology, 2019, 21, vi12-vi12.	1.2	3
56	Therapeutic Targeting of TGFÎ² Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas. Clinical Cancer Research, 2019, 25, 7189-7201.	7.0	33
57	Closed-loop cavitation control for focused ultrasound-mediated bloodâ€“brain barrier opening by long-circulating microbubbles. Physics in Medicine and Biology, 2019, 64, 045012.	3.0	18
58	Complementary and alternative medicine use by glioma patients in Switzerland. Neuro-Oncology Practice, 2019, 6, 237-244.	1.6	8
59	Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. Journal of Controlled Release, 2019, 295, 130-139.	9.9	72
60	Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology, 2019, 37, 2021-2021.	1.6	7
61	EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2019, 37, TPS2072-TPS2072.	1.6	6
62	Validation and revision of the RANO Leptomeningeal Metastasis Group scorecard for response assessment.. Journal of Clinical Oncology, 2019, 37, e13546-e13546.	1.6	0
63	Transcriptional control of O⁶â€methylguanine <scp>DNA</scp> methyltransferase expression and temozolomide resistance in glioblastoma. Journal of Neurochemistry, 2018, 144, 780-790.	3.9	24
64	Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. European Journal of Cancer, 2018, 96, 64-72.	2.8	17
65	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. JAMA Oncology, 2018, 4, 495.	7.1	135
66	EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro-Oncology, 2018, 20, 445-456.	1.2	173
67	The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathologica, 2018, 135, 923-938.	7.7	36
68	NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma. Clinical Cancer Research, 2018, 24, 882-895.	7.0	73
69	NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. Cancer Research, 2018, 78, 1031-1043.	0.9	193
70	Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas. International Journal of Pharmaceutics, 2018, 536, 388-396.	5.2	12
71	RBTT-08. EORTC 1709/CCTG CE.8: A PHASE III TRIAL OF MARIZOMIB IN COMBINATION WITH STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY VERSUS STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi235-vi236.	1.2	0
72	IMMU-53. IMPACT OF TUMOR-TREATING FIELDS (TTFIELDS) ON THE IMMUNOGENICITY OF GLIOMA CELLS. Neuro-Oncology, 2018, 20, vi133-vi133.	1.2	1

#	Article	IF	Citations
73	RARE-19. CHEMOTHERAPY FOR SPINAL GLIOMAS IN ADULTS: A RETROSPECTIVE STUDY. Neuro-Oncology, 2018, 20, vi240-vi240.	1.2	1
74	CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi48-vi49.	1.2	0
75	ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA,) Tj ETQq1 1 0.784314 rgBT /O	1.2	1
76	ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIOTHERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL. Neuro-Oncology, 2018, 20, vi14-vi14.	1.2	0
77	QOLP-27. USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE IN GLIOMA PATIENTS. Neuro-Oncology, 2018, 20, vi220-vi220.	1.2	0
78	Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma. Blood, 2018, 132, 2744-2753.	1.4	27
79	A tissue-based draft map of the murine MHC class I immunopeptidome. Scientific Data, 2018, 5, 180157.	5.3	45
80	A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results.. Journal of Clinical Oncology, 2018, 36, e14083-e14083.	1.6	4
81	Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2013-2013.	1.6	0
82	Sensitization of glioblastoma to alkylating chemotherapy by ultrasound-mediated delivery of therapeutic liposomes.. Journal of Clinical Oncology, 2018, 36, e14061-e14061.	1.6	0
83	Glioblastoma in the era of bevacizumab: An epidemiological study in the Canton of Zurich, Switzerland, 2010-2014.. Journal of Clinical Oncology, 2018, 36, e14062-e14062.	1.6	0
84	Long-term control and partial remission after initial pseudoprogression of glioblastoma by antiâ€“PD-1 treatment with nivolumab. Neuro-Oncology, 2017, 19, now265.	1.2	32
85	Biological activity of tumor-treating fields in preclinical glioma models. Cell Death and Disease, 2017, 8, e2753-e2753.	6.3	79
86	Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1815-1821.	2.5	57
87	Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nature Reviews Neurology, 2017, 13, 363-374.	10.1	125
88	Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. Neuro-Oncology, 2017, 19, 1338-1349.	1.2	44
89	Management of Elderly Patients with Glioblastoma. Current Neurology and Neuroscience Reports, 2017, 17, 35.	4.2	12
90	Biological Role and Therapeutic Targeting of TGF-Î²3 in Glioblastoma. Molecular Cancer Therapeutics, 2017, 16, 1177-1186.	4.1	47

#	Article	IF	Citations
91	The network of immunosuppressive pathways in glioblastoma. Biochemical Pharmacology, 2017, 130, 1-9.	4.4	76
92	Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. Journal of the National Cancer Institute, 2017, 109, 1-4.	6.3	51
93	Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: Efficacy and imaging analyses of the ARTE trial.. Journal of Clinical Oncology, 2017, 35, 2014-2014.	1.6	1
94	The value of ¹⁸F-fluordesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS).. Journal of Clinical Oncology, 2017, 35, 2076-2076.	1.6	0
95	Constitutive IFN signaling to modulate the immunogenicity of glioma cells.. Journal of Clinical Oncology, 2017, 35, e13528-e13528.	1.6	0
96	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget, 2016, 7, 15018-15032.	1.8	62
97	ACTR-18. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: AN UPDATE FROM THE BRAIN TUMOR FUNDERSâ€™ COLLABORATIVE CONSORTIUM. Neuro-Oncology, 2016, 18, vi5-vi5.	1.2	0
98	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 2016, 18, now133.	1.2	130
99	Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer, 2016, 122, 2206-2215.	4.1	77
100	Pharmacotherapies for the treatment of glioblastoma â€“ current evidence and perspectives. Expert Opinion on Pharmacotherapy, 2016, 17, 1259-1270.	1.8	24
101	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clinical Cancer Research, 2016, 22, 4797-4806.	7.0	105
102	Chemotherapy for intracranial ependymoma in adults. BMC Cancer, 2016, 16, 287.	2.6	23
103	Immunological effects of chemotherapy and radiotherapy against brain tumors. Expert Review of Anticancer Therapy, 2016, 16, 1087-1094.	2.4	30
104	Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology, 2016, 34, 3107-3108.	1.6	2
105	Immunotherapy of Brain Cancer. Oncology Research and Treatment, 2016, 39, 326-334.	1.2	14
106	Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. Journal of Neuro-Oncology, 2016, 129, 165-171.	2.9	28
107	Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. Neuro-Oncology, 2016, 18, 744-751.	1.2	58
108	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2016, 34, 731-739.	1.6	159

#	Article	IF	Citations
109	Prioritizing and selecting likely novel miRNAs from NGS data. Nucleic Acids Research, 2016, 44, e53-e53.	14.5	52
110	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. Oncotarget, 2016, 7, 82028-82045.	1.8	21
111	Control of glioma cell migration and invasiveness by GDF-15. Oncotarget, 2016, 7, 7732-7746.	1.8	40
112	MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. Oncotarget, 2016, 7, 12937-12950.	1.8	58
113	Direct contact with perivascular tumor cells enhances integrin Î±vÎ²3 signaling and migration of endothelial cells. Oncotarget, 2016, 7, 43852-43867.	1.8	28
114	Intravenous vs. intra-arterial methotrexate-based chemotherapy regimens for newly diagnosed primary central nervous system lymphoma.. Journal of Clinical Oncology, 2016, 34, e13505-e13505.	1.6	0
115	ATPS-73BIOLOGICAL ACTIVITY OF TUMOR-TREATING FIELDS (TTFIELDS) IN GLIOMA MODELS IN A PRECLINICAL SETTING. Neuro-Oncology, 2015, 17, v34.3-v34.	1.2	13
116	Management of diffusely infiltrating glioma in the elderly. Current Opinion in Oncology, 2015, 27, 502-509.	2.4	8
117	Immunotherapy for glioblastoma. Current Opinion in Neurology, 2015, 28, 639-646.	3.6	25
118	Interferon-Î² Modulates the Innate Immune Response against Glioblastoma Initiating Cells. PLoS ONE, 2015, 10, e0139603.	2.5	11
119	Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. Neuro-Oncology, 2015, 17, 1016-1021.	1.2	46
120	New frontiers in neurooncology. Current Opinion in Neurology, 2015, 28, 626-627.	3.6	0
121	Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro-Oncology, 2015, 17, 1007-1015.	1.2	38
122	Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. European Journal of Cancer, 2015, 51, 382-390.	2.8	31
123	Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. Annals of Hematology, 2015, 94, 409-414.	1.8	19
124	Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology, 2015, 84, 1242-1248.	1.1	94
125	Corticosteroid use in neuro-oncology: an update. Neuro-Oncology Practice, 2015, 2, 6-12.	1.6	51
126	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.. Journal of Clinical Oncology, 2015, 33, 2001-2001.	1.6	9

#	Article	IF	Citations
127	Long-term survival in patients with primary CNS lymphoma: Results from the G-PCNSL-SG1 trial.. Journal of Clinical Oncology, 2015, 33, 2032-2032.	1.6	3
128	Glioblastoma in the Canton of Zurich, Switzerland, revisited (2005-2009).. Journal of Clinical Oncology, 2015, 33, e13025-e13025.	1.6	2
129	Management of neoplastic meningitis. Chinese Clinical Oncology, 2015, 4, 26.	1.2	25
130	Clinical Reasoning: A 30-year-old woman with recurrent seizures and a cerebral lesion progressing over 2 decades. Neurology, 2014, 82, e56-60.	1.1	0
131	Addition of lomustine for bevacizumab-refractory recurrent glioblastoma. Acta OncolÃ³gica, 2014, 53, 1436-1440.	1.8	9
132	Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro-Oncology, 2014, 16, 584-588.	1.2	70
133	Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma. Chemotherapy, 2014, 60, 375-378.	1.6	13
134	Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. Neuro-Oncology, 2014, 16, viii14-viii19.	1.2	77
135	How Stemlike Are Sphere Cultures From Long-term Cancer Cell Lines? Lessons From Mouse Glioma Models. Journal of Neuropathology and Experimental Neurology, 2014, 73, 1062-1077.	1.7	15
136	Challenges in the treatment of elderly patients with primary central nervous system lymphoma. Current Opinion in Neurology, 2014, 27, 697-701.	3.6	30
137	Treatment of Primary CNS Lymphoma. Current Treatment Options in Neurology, 2014, 16, 277.	1.8	17
138	Interferon-Î² Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells. Molecular Cancer Therapeutics, 2014, 13, 948-961.	4.1	47
139	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 2014, 128, 561-571.	7.7	176
140	Postranslationally Modified Proteins in the Central Nervous System (CNS) Are the Dominant Antigenic Target/Stimulus of the B-Cell Receptor (BCR) in Primary CNS Lymphomas (PCNSL) Providing Strong Evidence for the Role of Chronic Autoantigenic Stimulation As an Early Step in the Pathogenesis of Aggressive B-Cell Lymphomas. Blood, 2014, 124, 142-142.	1.4	9
141	Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.. Journal of Clinical Oncology, 2014, 32, 2003-2003.	1.6	13
142	MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. Oncotarget, 2014, 5, 7651-7662.	1.8	79
143	Anaplastic Oligodendroglioma: A New Treatment Paradigm and Current Controversies. Current Treatment Options in Oncology, 2013, 14, 505-513.	3.0	16
144	Integrin control of the transforming growth factor-Î² pathway in glioblastoma. Brain, 2013, 136, 564-576.	7.6	94

#	Article	IF	Citations
145	Î±vâ€Integrin isoform expression in primary human tumors and brain metastases. International Journal of Cancer, 2013, 133, 2362-2371.	5.1	94
146	Tumor-associated edema in brain cancer patients: pathogenesis and management. Expert Review of Anticancer Therapy, 2013, 13, 1319-1325.	2.4	41
147	Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, 2092-2092.	1.6	2
148	Induction of atypical anoikis in glioma cells through inhibition of integrin functions.. Journal of Clinical Oncology, 2013, 31, 2079-2079.	1.6	0
149	Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology, 2012, 79, 890-896.	1.1	73
150	Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro-Oncology, 2012, 14, 1481-1484.	1.2	192
151	Immunology of brain tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 45-51.	1.8	14
152	Pathogenesis and management of primary CNS lymphoma. Expert Review of Anticancer Therapy, 2012, 12, 623-633.	2.4	21
153	Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Journal of Neurochemistry, 2012, 122, 444-455.	3.9	120
154	HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. Journal of Neuroimmunology, 2012, 250, 27-34.	2.3	39
155	Effect of the integrin inhibitor cilengitide on TGF-beta signaling.. Journal of Clinical Oncology, 2012, 30, 2055-2055.	1.6	42
156	Elderly patients with primary CNS lymphoma: Results from the G-PCNSL-SG-1 trial.. Journal of Clinical Oncology, 2012, 30, 2007-2007.	1.6	0
157	Geriatric neuro-oncology. Current Opinion in Neurology, 2011, 24, 599-604.	3.6	25
158	A specific miRNA signature in the peripheral blood of glioblastoma patients. Journal of Neurochemistry, 2011, 118, 449-457.	3.9	177
159	APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro-Oncology, 2011, 13, 155-164.	1.2	42
160	Steroids in neurooncology: actions, indications, side-effects. Current Opinion in Neurology, 2010, 23, 597-602.	3.6	85
161	Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. Journal of Neurosurgery, 2010, 113, 280-285.	1.6	30
162	Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. Journal of Neuro-Oncology, 2010, 97, 389-392.	2.9	72

#	Article	IF	Citations
163	GDF-15 Contributes to Proliferation and Immune Escape of Malignant Gliomas. Clinical Cancer Research, 2010, 16, 3851-3859.	7.0	125
164	Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood, 2010, 115, 5005-5011.	1.4	325
165	SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity In vitro and In vivo. Clinical Cancer Research, 2009, 15, 6609-6618.	7.0	19
166	Seizure-Induced Periorbital Petechial Rash. European Neurology, 2009, 61, 317-317.	1.4	12
167	ACNU-based chemotherapy for recurrent glioma in the temozolomide era. Journal of Neuro-Oncology, 2009, 92, 45-48.	2.9	43
168	Anticoagulation for radiation-induced neurotoxicity revisited. Journal of Neuro-Oncology, 2008, 90, 357-362.	2.9	21
169	A series of patients with subpial hemorrhage: Clinical manifestation, neuroradiological presentation and therapeutic implications. Journal of Neurology, 2008, 255, 1018-1022.	3.6	19
170	Malignant Glioma Cells Counteract Antitumor Immune Responses through Expression of Lectin-Like Transcript-1. Cancer Research, 2007, 67, 3540-3544.	0.9	87
171	Regeneration and Tolerance Factor: A Novel Mediator of Glioblastoma-Associated Immunosuppression. Cancer Research, 2006, 66, 3852-3858.	0.9	24
172	Treatment of gliomas with temozolomide: rather at sunrise or sunset?. Neuro-Oncology Practice, 0, , .	1.6	0